Shamburg News · 8-K filed Nov 12, 2026, 4:11 PM EST

Bolt Biotherapeutics Reports Q3 2026 Results and Completes Prana Therapies Acquisition

BOLT · Bolt Biotherapeutics, Inc.

  • Earnings
  • Acquisition
  • Financing
  • Other event
  • Materiality: high

Bolt Biotherapeutics reported a net loss of $4.4 million for the quarter ended September 30, 2026, compared with $7.1 million a year earlier, and collaboration revenue of zero versus $2.2 million. In October 2026 the company completed its acquisition of Prana Therapies and a concurrent private placement with approximately $120 million in gross proceeds. The company stated that the financing is expected to fund operations into 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458403.

Written from the filing by Shamburg Markets. Figures are as reported by the company.